Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, outlines the findings of the Phase I UNIVERSAL trial (NCT04093596) of ALLO-715, a B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma. Initial lymphodepletion involved fludarabine, cyclophosphamide and ALLO-647 (FCA), with the medial time for starting therapy being 5 days after enrollment. No reports of graft-versus-host disease (GvHD), or neurotoxicity were observed, and 40% of patients achieved a very good partial response (VGPR). Dr Hari additionally discusses potential addition of γ-secretase inhibitors to improve CAR T-cell efficacy. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.